RO5509554: Phase I/II data

Data from 18 evaluable patients with inoperable progressive or relapsing pigmented villonodular synovitis (PVNS) in the open-label, dose-escalation, French Phase Ia/Ib BP27772 trial or an extension cohort of the trial showed that IV RG7155 every 2 weeks led to 15 partial responses. The MTD was not reached and the optimal biological dose was 1,000 mg for the extension cohort. RG7155 was well tolerated with asthenia, periorbital and peripheral edema and pruritus reported as the most common adverse events. There were 4 serious adverse events of periorbital edema, appendicitis, lupus erythematosis and erythema at doses higher than the optimal biological dose. BP27772 has enrolled 124 patients with advanced solid tumors. PVNS is a proliferative neoplastic tumor that affects the synovium and tendon sheaths in young and middle-aged adults. Data were presented at the American Society of Clinical Oncology meeting in Chicago and published in Cancer Cell. ...